Tämä sivu käännettiin automaattisesti, eikä käännösten tarkkuutta voida taata. Katso englanninkielinen versio lähdetekstiä varten.

An Efficacy and Safety Study for Tapentadol Extended Release (JNS024ER) in Chronic Pain Participants

perjantai 10. toukokuuta 2013 päivittänyt: Janssen Pharmaceutical K.K.

Phase II Study of JNS024ER in Japanese Subjects With Chronic Pain Due to Osteoarthritis of the Knee or Low Back Pain

The purpose of this study is to evaluate the efficacy, safety and to explore the pharmacokinetics (how drugs are absorbed in the body, how they are distributed within the body and how they are removed from the body over time) of tapentadol hydrochloride extended release (ER) tablets in Japanese participants with moderate to severe chronic pain due to osteoarthritis (disorder in which the joints become painful and stiff) of knee or low back pain.

Tutkimuksen yleiskatsaus

Tila

Valmis

Ehdot

Interventio / Hoito

Yksityiskohtainen kuvaus

This is a randomized (study drug assigned by chance), multi-center (when more than one hospital or medical school team works on a medical research study), double-blind (neither physician nor participant knows the name of the assigned drug), placebo-control (participants are randomly assigned to a test treatment or to an identical-appearing treatment that does not contain the test drug), parallel-group (each group of participants will be treated at the same time) comparison study in participants with chronic pain due to osteoarthritis of knee or low back pain. The study duration will be of 14 weeks, which consists of a screening period of 1 week during which the participants will be evaluated for study eligibility, a treatment period of 12 weeks and a follow-up period of 1 week. The treatment period will consist of titration period (from the initiation of the study treatment to determination of the individual's maintenance dose) and maintenance period (from completion of the titration period to the completion of the treatment period). An optimal dose (maintenance dose) will be determined for each participant during the titration period and the treatment will be continued at the maintenance dose to assess the efficacy and safety. Tapentadol hydrochloride ER tablets 25 to 250 milligram or placebo will be administered orally twice daily. Efficacy and safety of the participants will primarily be evaluated by change from baseline in average pain intensity score based on 11-point Numerical Rating Scale (NRS) and Clinical Opiate Withdrawal Scale (COWS), respectively. Participants' safety will be monitored throughout the study.

Opintotyyppi

Interventio

Ilmoittautuminen (Todellinen)

91

Vaihe

  • Vaihe 2

Yhteystiedot ja paikat

Tässä osiossa on tutkimuksen suorittajien yhteystiedot ja tiedot siitä, missä tämä tutkimus suoritetaan.

Opiskelupaikat

  • Japani
      • Aichi, Japani
      • Amagasaki, Japani
      • Chiba, Japani
      • Chiba N/A, Japani
      • Chikushi, Japani
      • Edogawa, Japani
      • Fukuoka, Japani
      • Fukushima, Japani
      • Hiratsuka, Japani
      • Kawasaki, Japani
      • Koto, Japani
      • Matsudo, Japani
      • Meguro, Japani
      • Minato-Ku, Japani
      • Niigata, Japani
      • Niigata N/A, Japani
      • Osaka, Japani
      • Sagamihara, Japani
      • Shibuya, Japani
      • Shinjuku-Ku, Japani
      • Toshima-Ku, Japani

Osallistumiskriteerit

Tutkijat etsivät ihmisiä, jotka sopivat tiettyyn kuvaukseen, jota kutsutaan kelpoisuuskriteereiksi. Joitakin esimerkkejä näistä kriteereistä ovat henkilön yleinen terveydentila tai aiemmat hoidot.

Kelpoisuusvaatimukset

Opintokelpoiset iät

20 vuotta ja vanhemmat (Aikuinen, Vanhempi Aikuinen)

Hyväksyy terveitä vapaaehtoisia

Ei

Sukupuolet, jotka voivat opiskella

Kaikki

Kuvaus

Inclusion Criteria:

  • Participants with chronic pain due to osteoarthritis of knee or low back pain continuing for at least 12 weeks before informed consent
  • Participants who did not achieve adequate analgesia (pain control) with routine treatment with an oral non-opioid analgesic (drug used to control pain) at its usual upper-limit dose or at an adequate fixed dose for at least 14 consecutive days during the 12 weeks before informed consent
  • Participants who have not experienced treatment with conventional opioids, except for short term use of opioid analgesics for treatment of post-operative acute pain more than 30 days before consent or temporary use of codeine phosphate or dihydrocodeine phosphate for purposes other than pain relief (e.g. for antitussive) more than 2 days before informed consent
  • Participants with average pain intensity score of greater than or equal to 5 on an 11-point Numerical Rating Scale (NRS) during 48 hours before informed consent and are considered requiring opioid treatment by the Investigator
  • Participants who are able to visit the medical institutions throughout the study period

Exclusion Criteria:

  • Participants who are taking a monoamine oxidase inhibitor within 14 days before informed consent
  • Participants with current or a history of epilepsy or seizure disorders
  • Participants suspected with intracranial hypertension (e.g. traumatic encephalopathy)
  • Participants with uncontrolled or clinically significant arrhythmia (irregular heart rate)
  • Participants with moderate to severe liver dysfunction or severe renal dysfunction

Opintosuunnitelma

Tässä osiossa on tietoja tutkimussuunnitelmasta, mukaan lukien kuinka tutkimus on suunniteltu ja mitä tutkimuksella mitataan.

Miten tutkimus on suunniteltu?

Suunnittelun yksityiskohdat

  • Ensisijainen käyttötarkoitus: Hoito
  • Jako: Satunnaistettu
  • Inventiomalli: Rinnakkaistehtävä
  • Naamiointi: Kaksinkertainen

Aseet ja interventiot

Osallistujaryhmä / Arm
Interventio / Hoito
Placebo Comparator: Plasebo
Lääke: Placebo
Placebo matched to tapentadol hydrochloride ER tablets 25 to 250 mg will be administered orally twice daily for 12 weeks. Dose will be adjusted as per Investigator's discretion.
Kokeellinen: Tapentadol Hydrochloride
Lääke: Tapentadol Hydrochloride
Tapentadol hydrochloride extended release (ER) tablets 25 to 250 milligram (mg) will be administered orally twice daily for 12 weeks. Dose will be adjusted as per Investigator's discretion.

Mitä tutkimuksessa mitataan?

Ensisijaiset tulostoimenpiteet

Tulosmittaus
Toimenpiteen kuvaus
Aikaikkuna
Change From Baseline in 11-point Numerical Rating Scale (NRS) at Week 12
Aikaikkuna: Baseline, Week 12
Participants were asked to assess the average pain intensity on a 11-point NRS ranging from 0 (no pain) to 10 (maximum pain imaginable) by selecting a number applicable to their pain on the scale. The mean pain intensity during the past 74 hours (3 days) was evaluated at Baseline and the mean pain intensity during the past 12 hours was evaluated at subsequent study visits.
Baseline, Week 12

Toissijaiset tulostoimenpiteet

Tulosmittaus
Toimenpiteen kuvaus
Aikaikkuna
Change From Baseline in 11-point Numerical Rating Scale (NRS)
Aikaikkuna: Baseline, Week 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11
Participants were asked to assess the average pain intensity on a 11-point NRS ranging from 0 (no pain) to 10 (maximum pain imaginable) by selecting a number applicable to their pain on the scale. The mean pain intensity during the past 74 hours (3 days) was evaluated at Baseline and the mean pain intensity during the past 12 hours was evaluated at subsequent study visits.
Baseline, Week 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11
Percentage of Participants With Response Based on 11-point Numerical Rating Scale (NRS)
Aikaikkuna: Week 12
Percentage of participants with improvement in mean NRS score by greater than or equal to 30 percent or 50 percent in the last week from Baseline were considered as responders. Participants were asked to assess the average pain intensity on a 11-point NRS ranging from 0 (no pain) to 10 (maximum pain imaginable) by selecting a number applicable to their pain on the scale.
Week 12
Number of Participants With Categorical Scores on Patient's Global Impression of Change (PGIC) Scale
Aikaikkuna: Week 8, Week 12
The PGIC is a 7-point scale that requires the participants to assess how much their illness has improved or worsened relative to a Baseline state at the beginning of the intervention. The response options are 1 = very much improved, 2 = much improved, 3 = minimally improve, 4 = no change, 5 = minimally worse, 6 = much worse, and 7 = very much worse.
Week 8, Week 12
Number of Participants With Response Based on Physician's Global Assessment Scale
Aikaikkuna: Week 8, Week 12
Physician's Global Assessment Scale assesses the therapeutic efficacy (effectiveness) of the study drug for pain control on a 2-point scale of "effective" and "not effective".
Week 8, Week 12
Number of Participants With Presence of Pain Based on Brief Pain Inventory-Short Form (BPI-sf) Scale
Aikaikkuna: Baseline, Week 12
BPI-sf is a self-evaluated pain assessment form consisting of 15 items (item 1 - presence of pain, item 2 - pain location, items 3 to 6 - pain severity, item 7 - status of pain treatment, item 8 - efficacy of pain treatment, and items 9a to 9g - interference of pain with daily life). Item 1 for presence of pain assesses the question: "Do you have any pain today other than everyday kinds of pain?" on a 2-point scale of "yes" or "no".
Baseline, Week 12
Number of Participants With 50 Percent Pain Relief Based on Brief Pain Inventory-Short Form (BPI-sf) Scale
Aikaikkuna: Baseline, Week 12
BPI-sf is a self-evaluated pain assessment form consisting of 15 items (item 1 - presence of pain, item 2 - pain location, items 3 to 6 - pain severity, item 7 - status of pain treatment, item 8 - efficacy of pain treatment, and items 9a to 9g - interference of pain with daily life). Item 8 for efficacy of pain treatment assesses number of participants with at least 50 percent pain relief during the last 24 hours on a scale ranging from 0 percent (no relief) to 100 percent (complete relief).
Baseline, Week 12
Change From Baseline in Brief Pain Inventory-Short Form (BPI-sf) Total Score at Week 12
Aikaikkuna: Baseline, Week 12
BPI-sf consists of 15 items (item 1 - presence of pain, item 2 - pain location, items 3 to 6 - pain severity, item 7 - status of pain treatment, item 8 - efficacy of pain treatment, and items 9a to 9g - interference of pain with daily life). Total score is defined as the mean scores from items 3, 4, 5, 6 and 9 recorded on an 11-point scale where 0 = no pain and 10 = pain as bad as you can imagine. Negative change indicates an improvement in pain.
Baseline, Week 12
Change From Baseline in Sleep Latency Based on Sleep Questionnaire at Week 12
Aikaikkuna: Baseline, Week 12
Sleep Latency was addressed by the question: "How long after bedtime/lights out did you fall asleep last night?" and the change from Baseline in sleep latency was reported. Decrease in time indicated improvement.
Baseline, Week 12
Change From Baseline in Time Slept Based on Sleep Questionnaire at Week 12
Aikaikkuna: Baseline, Week 12
Time slept was addressed by the question: "How long did you sleep last night?" and the change from Baseline in time slept was reported.
Baseline, Week 12
Number of Participants With Awakenings Based on Sleep Questionnaire
Aikaikkuna: Baseline, Week 12
Number of awakenings was addressed by the question: "How many times did you wake up during the night?'' and lesser number signified better sleep.
Baseline, Week 12
Number of Participants With Response Based on Overall Quality of Sleep Questionnaire
Aikaikkuna: Baseline, Week 12
Overall quality of sleep was addressed by the question: "Please rate the overall quality of your sleep last night" and participants could choose one of the following options: excellent, good, fair or poor.
Baseline, Week 12
Change From Baseline in Short Form-36 Health Survey Version 2 (SF-36v2) Scores at Week 12
Aikaikkuna: Baseline, Week 12
SF-36v2 is 36-item form related to 8 health concepts (physical functioning, role physical, role emotional, general health, social functioning, bodily pain, vitality, mental health) and 2 summary scores (physical and mental component summary). Physical functioning, role physical and bodily pain contribute to physical component; role emotional, social functioning and mental health contribute to mental component; and social functioning, vitality, and general health contribute to both. All scores are based on a scale from 0 to 100, with higher scores defining more favorable health state.
Baseline, Week 12
Change From Baseline in Western Ontario MacMaster Questionnaire (WOMAC) Global Score at Week 12
Aikaikkuna: Baseline, Week 12
WOMAC is a self administered 24-item questionnaire used to evaluate participants with osteoarthritis of the knee. It consists of 3 subscales: pain (5 items), joint stiffness (2 items), and physical function (17 items). Each item is assessed on a 5-point scale from 0 to 4. The global score assesses pain, disability and joint stiffness and ranges from 0 to 96. Higher scores indicate that a symptom is bothersome and physically disabling.
Baseline, Week 12
Change From Baseline in Roland Morris Disability Questionnaire (RDQ) Score at Week 12
Aikaikkuna: Baseline, Week 12
RDQ scale is used to assess the impact of low back pain on daily activities by participants. The scale consists of 24 item questionnaire with options as "Yes"/"No" where "Yes" is counted as 1 point. The total score ranged from 0 to 24, with higher scores indicating greater disability.
Baseline, Week 12

Muut tulostoimenpiteet

Tulosmittaus
Toimenpiteen kuvaus
Aikaikkuna
Number of Participants With Response Based on Clinical Opioid Withdrawal Symptoms Questionnaire (COWS)
Aikaikkuna: Week 12
COWS is an 11-item questionnaire for clinical assessment of withdrawal symptoms. Total score is calculated by adding the scores of all the 11-items. The severity of withdrawal symptoms is categorized using values of total score as: 0-4 = no withdrawal, 5-12 = mild, 13-24 = moderate, 25-36 = moderately severe, and 37-48 = severe withdrawal.
Week 12
Serum Concentration of Tapentadol
Aikaikkuna: Week 2, 4, 8, 12
Week 2, 4, 8, 12

Yhteistyökumppanit ja tutkijat

Täältä löydät tähän tutkimukseen osallistuvat ihmiset ja organisaatiot.

Sponsori

Janssen Pharmaceutical K.K.

Opintojen ennätyspäivät

Nämä päivämäärät seuraavat ClinicalTrials.gov-sivustolle lähetettyjen tutkimustietueiden ja yhteenvetojen edistymistä. National Library of Medicine (NLM) tarkistaa tutkimustiedot ja raportoidut tulokset varmistaakseen, että ne täyttävät tietyt laadunvalvontastandardit, ennen kuin ne julkaistaan ​​julkisella verkkosivustolla.

Opi tärkeimmät päivämäärät

Opiskelun aloitus

Torstai 1. huhtikuuta 2010

Ensisijainen valmistuminen (Todellinen)

Keskiviikko 1. joulukuuta 2010

Opintojen valmistuminen (Todellinen)

Keskiviikko 1. joulukuuta 2010

Opintoihin ilmoittautumispäivät

Ensimmäinen lähetetty

Torstai 22. huhtikuuta 2010

Ensimmäinen toimitettu, joka täytti QC-kriteerit

Torstai 13. toukokuuta 2010

Ensimmäinen Lähetetty (Arvio)

Maanantai 17. toukokuuta 2010

Tutkimustietojen päivitykset

Viimeisin päivitys julkaistu (Arvio)

Tiistai 14. toukokuuta 2013

Viimeisin lähetetty päivitys, joka täytti QC-kriteerit

Perjantai 10. toukokuuta 2013

Viimeksi vahvistettu

Keskiviikko 1. toukokuuta 2013

Lisää tietoa

Tähän tutkimukseen liittyvät termit

Avainsanat

Muita asiaankuuluvia MeSH-ehtoja

Muut tutkimustunnusnumerot

  • CR016999
  • JNS024ER-JPN-N21 (Muu tunniste: Janssen Pharmaceutical K.K., Japan)

Nämä tiedot haettiin suoraan verkkosivustolta clinicaltrials.gov ilman muutoksia. Jos sinulla on pyyntöjä muuttaa, poistaa tai päivittää tutkimustietojasi, ota yhteyttä register@clinicaltrials.gov. Heti kun muutos on otettu käyttöön osoitteessa clinicaltrials.gov, se päivitetään automaattisesti myös verkkosivustollemme .

Kliiniset tutkimukset Kipu

Kliiniset tutkimukset Tapentadol Hydrochloride

Hae vastaavia kokeiluja

Sponsorit ja yhteistyökumppanit

Sairaudet

Huumeiden interventiot

CROs by country

CROs in Uzbekistan

Ehdot

Harvinaiset sairaudet

Huumeiden interventiot

Ravintolisät

Sponsori / yhteistyökumppanit

Sijainnit

Tilaa